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Endothelial progenitor cells (EPCs) have great clinical value because they can be used as diagnostic biomarkers and as a cellular
therapy for promoting vascular repair of ischaemic tissues. However, EPCs also have an additional research value in vascular
disease modelling to interrogate human disease mechanisms. The term EPC is used to describe a diverse variety of cells, and we
have identiﬁed a speciﬁc EPC subtype called outgrowth endothelial cell (OEC) as the best candidate for vascular disease modelling
because of its high-proliferative potential and unambiguous endothelial commitment. OECs are isolated from human blood and
can be exposed to pathologic conditions (forward approach) or be isolated from patients (reverse approach) in order to study
vascular human disease. The use of OECs for modelling vascular disease will contribute greatly to improving our understanding
of endothelial pathogenesis, which will potentially lead to the discovery of novel therapeutic strategies for vascular diseases.
1.Introduction
There is growing interest in endothelial progenitor cells
(EPCs) because of their relevant diagnostic and therapeutic
clinical applications. The association of EPCs with cardio-
vascular events [1] and cancer progression [2] demonstrates
that EPCs have potential as both diagnostic and prognostic
biomarkers. Furthermore, there are many preclinical and
clinical trials that have reported beneﬁts for a cell therapy
based on delivering EPCs to ischaemic tissues such as heart
[3], brain [4], retina [5], and limbs [6]. In the case of
ischaemic heart disease and ischaemic limbs, despite con-
ﬂicting data, meta-analysis indicated that an EPC-based
cytotherapy is feasible, safe, and beneﬁcial [7, 8]. This paper
will not further discuss the diagnostic and therapeutic value
of EPCs, but will focus on a lesser-known application for
EPCs, that is, their potential for modelling human disease
pathogenesis.Creatingcellularmodelsofhumandiseaseisan
important research area where EPCs can be readily used and
allows for the study of cellular and molecular mechanisms
of vascular disease in a “Petri-dish”. Here, we will discuss
methodology for EPC isolation and diﬀerent cell subtypes
and also present strategies to use EPCs as valuable tools to
model vascular disease.
2. EPCsfor DiseaseModelling
Study of human disease using in vitro-based models usually
requires large quantities of cells. This is why classically
immortalisedcelllineshadtobeestablishedforthispurpose.
However,thesecelllineslackanumberoftumoursuppressor
genes or overexpress oncogenes, which is a major drawback
when assessing cellular proliferation and survival. Therefore,
recent interest has drifted to the usage of human embryonic
stem (hES) and induced pluripotent stem (iPS) cells [9, 10],
as they can theoretically be converted into any somatic cell
type.WebelievethatEPCs,asaspeciﬁctypeofadultvascular
stem cell [11], have great potential for modelling human
disease. EPCs are easily isolated from peripheral and umbil-
ical cord blood, they are highly proliferative, possess a stable
and diploid karyotype, represent a very homogeneous cell
population that is endothelial lineage-committed, and are
amenable to in vitro manipulation and genetic modiﬁcation.
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cell function can be consistently studied through EPCs, as
there is no reprogramming process required, which removes
methylation or acetylation events, as is the case for iPS cells.
3. Isolation of EPCs
EPCs are isolated using two main methodologies: (a) cell
sorting technology using diﬀerent cell surface markers or (b)
in vitro cell culture of the blood mononuclear cell fraction
using speciﬁc substrates and media.
EPC cell sorting is dependent on the type and number of
markers used. However, since there is no agreed consensus
regarding the most appropriate combination of EPC-linked
markers [12], diﬀerent research teams have been sorting
diﬀerent cells using a diverse array of markers. Therefore,
although sorted cells are all named EPCs, they actually rep-
resent distinct cell types, and this is demonstrated by the lack
of consistency in reported studies using “EPCs” in various in
vitro and animal model-based systems.
An alternative approach for isolating EPCs is cell culture.
This is based on diﬀerential adhesion to speciﬁc substrates
and the subsequent growth potential of isolated cells in
culture. Using this methodology, two distinct types of EPCs
have been identiﬁed [13, 14]. Early EPCs that appear within
one week in culture are spindle-shaped cells that exhibit
some endothelial properties in vitro, such as AcLDL uptake,
Isolectin binding, and appearance of VEGFR2/CD31 on the
cell surface. Despite these endothelial characteristics, these
cells retain their haematopoietic nature, as demonstrated by
high expression of CD14 and CD45. In fact, we have recently
shown that early EPCs represent M2 alternative-activated
macrophagesandproposedtheirrenamingasmyeloidangio-
genic cells (MACs) [15]. Other names for this cell type
commonly found in the literature are circulating angiogenic
cells, haematopoietic EPCs, proangiogenic monocytes, and
vascular accessory cells [16].
The other EPC subtype is known as outgrowth endothe-
lial cells (OECs) [17]. OECs appear within four weeks in cul-
ture as a cobblestone-shaped cell monolayer, exhibiting great
proliferative potential and an unambiguous commitment to
the endothelial lineage [18, 19]. Many studies have clearly
described the OEC immunophenotype as being highly pos-
itive for the endothelial markers VE-cadherin, vWF, CD31,
CD36, CD105, CD146, VEGFR2, and Tie2; negative for
haematopoietic markers CD45 and CD14; and exhibit some
expression of progenitor cell markers CD34, CD117, and
CD133 [5, 17, 20]. OECs are also known as endothe-
lial colony-forming cells (ECFCs), late EPCs, and non-
haematopoietic EPCs. OECs are diﬀerent from circulating
mature endothelial cells due to the fact that they have a
higher proliferative potential, shorter doubling time, and
single-cell cloning capacity in contrast to mature endothelial
cells that have limited proliferative potential [13, 17, 21]. Ad-
ditionally, OECs retain properties of immature cells, such as
greater responsiveness/sensitivity to VEGF, FGF-2, and PlGF
[21], and continued expression of progenitor cell markers
CD34, CD133, and CD117 [5].
OECs have been shown to possess de novo tubulogenic
capacity in vitro by forming three-dimensional tubular
structures where cells interact with each other through the
junction protein VE-cadherin and form a distinct vessel-
like lumen [22]. This de novo blood vessel formation is also
demonstrated in vivo where human OECs are transplanted
subcutaneously in a collagen-ﬁbronectin matrix into im-
munodeﬁcient mice and eﬃciently form perfused chimeric
blood vessels [18, 23, 24]. Using rhesus monkey-derived
OECs in this mouse experimental system, it was recently
shown that there was a decreased potential to form func-
tional capillaries with chronological age [25]. Most impor-
tantly, it has been demonstrated that OECs directly incorpo-
rate into damaged ischaemic vasculature in vivo as reported
using diﬀerent animal models such as the murine hind limb
ischaemia [13], rabbit carotid artery injury [26], the porcine
myocardialinfarction[27],andmurineretinalischaemia[5].
For the speciﬁc purpose of vascular disease modelling,
OECs should be the preferred EPC subtype to use, as they
are currently the only EPCs with both great proliferative
potential and unequivocal endothelial phenotype.
4.Approaches for DiseaseModellingwithOECs
In disease modelling, the classical “reverse” and “forward”
approaches used for hESCs are fully applicable to OECs
(Figure 1). The “reverse” approach is based on studying
OECs isolated from patients, so that “disease-speciﬁc” cells
are derived and compared to “disease-free” cells. This ap-
proach is very useful as it provides a meaningful insight
into physiopathology although it has two drawbacks. First,
isolating OECs from certain patient groups may be prob-
lematic. For example, it is well known that diabetic patients
have a lower number of circulating EPCs and when they
are isolated, these cells show dysfunctional responses [28,
29]. The second drawback is that isolated OECs from
patients are “already diseased”, and as the “reverse” approach
is fundamentally retrospective, it may not be possible to
accurately model early stages of a pathogenic process.
The “forward” approach consists of studying “disease-
free” OECs that are exposed to deﬁned disease-relevant
conditions, which can be as simple as environmental changes
(hypoxia, high glucose, and radiation) to more complex
genetic modiﬁcations by knocking down disease-related
genes. This approach is prospective and allows the study of
disease pathogenesis from early stages; however, there are
some technical challenges. Trying to mimic the pathologic
environmentcanproveverycomplicatedastheinvivomilieu
usually comprises a diverse variety of factors combined
together. Reproducing the in vivo environment in vitro re-
quires multicell type culture systems. Another diﬃculty ap-
pears when the disease of interest is non-cell autonomous
and therefore is directly dependent on diﬀerent cell-cell
interactions, and more than one cell type is needed for
disease development and progression. A strategy that could
easily address this latter issue of multiple cell types is the
adjuvant use of iPS cell methodologies [30]. Generation
of iPS cells and OECs from the same donor can provide
the means to study OECs in various cell culture settings,
including co-cultures with iPS cells or any other iPS cell-
derived somatic cell type. This has the advantage that allStem Cells International 3
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Figure 1: Strategies for the use of EPCs in vascular disease modelling. A speciﬁc EPC cell subtype called OEC can be isolated from human
peripheral blood of both healthy donors and patients. In the forward approach, “disease-free” OECs are exposed to disease-relevant
conditions or genetic modiﬁcations, while in the reverse approach “disease-speciﬁc” OECs are studied in comparison to “disease-free”
OECs.
the diﬀerent cell types studied alongside OECs will have the
same donor which is ideal to avoid possible immunological
responses arising from allogeneic transplantation.
While OECs can be studied directly, they can also indi-
rectly facilitate the study of other supportive cells that can
modulate vasculogenic activity in vitro or in vivo.A sw i t h
fully diﬀerentiated endothelial cells, angiogenic activity in
OECs can be directed by cytokines released from proximal
myeloid cells, mesenchymal stem cells (MSCs) [24, 31],
mesenchymal stromal cells, ﬁbroblasts [23], adipose stromal
cells [32], pericyte progenitors [33], astrocytes, neurons, and
MACs [15, 34]. Interestingly, a mechanism involving the
formation of nanotubes for the transport of organelles such
as mitochondria and lysosomes has also been reported [35–
37]. Delivery of miRNAs within microvesicles and exosomes
represent another way cells can communicate with OECs
[38, 39].
Despite these technical challenges, utilising OECs to gen-
erate cellular models of disease is an attractive methodology
that is already being used and optimised. We anticipate that
in the ﬁeld of vascularbiology, researcherswillfavour the use
of EPCs/OECs for disease modelling.
5.OECsUsedAsDiseaseCellularModels
OECs derived from patients with chronic myeloproliferative
disorders (CMD) [40] indicated that this disease targets
mainly the haematopoietic system, as the BCR-ABL rear-
rangement or JAK2-V617F mutation were not present in
OECs. This ﬁnding highlighted that OECs are not the
adult “haemangioblast”, but represent adult stem cells fully
committed to the endothelial lineage.
OECs from patients with hereditary haemorrhagic
telangiectasia(HHT)[41]revealedabnormalitiescompatible
with vascular lesions, such as decreased endoglin expression,
impaired TGF-β signalling, disorganised cytoskeleton, and
failure to form cord-like structures. These ﬁndings described
a molecular mechanism to explain small-vessel fragility and
frequent bleeding in these patients.
To elucidate the role of EPCs in the pathobiology of
pulmonary arterial hypertension (PAH), OECs were isolated
from peripheral blood of PAH patients with mutations in the
gene-encoding bone morphogenetic protein receptor type II
(BMPRII) and control subjects. OECs from PAH patients
with BMPRII mutations were hyperproliferative when com-
pared to controls. Furthermore, the matrigel angiogenesis
assay demonstrated that in vitro tube formation was also sig-
niﬁcantly impaired in OEC isolated from PAH patients [42].
Von Willebrand disease (vWD) is frequently associated
with angiodysplasia; therefore, the importance of vWF
expression was tested in endothelial cells and animal models.
vWF-deﬁcient cells showed enhanced angiogenesis in vitro,
and vWF-deﬁcient mice displayed increase angiogenesis in
vivo. These results were further conﬁrmed by isolating OECs
from patients with vWD [43] which showed increased in
vitro angiogenesis, proliferation, and migration.
To study the role of the diabetic environment in EPC
function, OECs were exposed to high glucose, and umbilical
cords of diabetic mothers were used as the EPC source to
isolate OECs that had previously experienced diabetic condi-
tionsinvivo[44].Resultsdemonstratedthatexposuretohigh
glucoseinvitrooradiabeticenvironmentinvivosigniﬁcantly
diminished OEC function such as colony formation, self-
renewal capacity, and capillary-like tube formation. This
study provided potential mechanistic insights into the long-
term cardiovascular complications observed in newborns of
diabetic pregnancies.4 Stem Cells International
6. Concluding Thoughts
OECs are a speciﬁc EPC sub-type that is starting to be used
forthestudyofvascularpathology.Weencourageresearchers
in the ﬁeld of vascular biology to apply their diﬀerent in vitro
and in vivo models of angiogenesis to OECs. Combination of
forwardandreverseapproachesforhumandiseasemodelling
with OECs is an eﬀective system for the study of vascular
disease pathogenesis. As with any new technology, we foresee
some technical challenges when establishing disease models
at the cellular level; nevertheless, we remain optimistic that
utilising OECs for vascular disease modelling will improve
our understanding of disease that subsequently leads to the
development of novel therapies.
Acknowledgments
This paper was supported by Fight for Sight, the Medical
Research Council (MRC), Juvenile Diabetes Research Foun-
dation, D.E.L. (NI), and the Sir Jules Thorn Trust.
References
[1] N. Werner, S. Kosiol, T. Schiegl et al., “Circulating endothelial
progenitor cells and cardiovascular outcomes,” The New Eng-
land Journal of Medicine, vol. 353, no. 10, pp. 999–1007, 2005.
[2] M. H. Strijbos, J. W. Gratama, J. Kraan, C. H. Lamers, M. A.
den Bakker, and S. Sleijfer, “Circulating endothelial cells in
oncology: pitfalls and promises,” British Journal of Cancer, vol.
98, no. 11, pp. 1731–1735, 2008.
[3] H. Sekiguchi, M. Ii, and D. W. Losordo, “The relative potency
and safety of endothelial progenitor cells and unselected mon-
onuclear cells for recovery from myocardial infarction and is-
chemiar,” Journal of Cellular Physiology, vol. 219, no. 2, pp.
235–242, 2009.
[4] Y. Fan, F. Shen, T. Frenzel et al., “Endothelial progenitor cell
transplantation improves long-term stroke outcome in mice,”
Annals of Neurology, vol. 67, no. 4, pp. 488–497, 2010.
[5] R. Medina, C. L. O’Neill, M. W. Humphreys, T. A. Gardiner,
and A. W. Stitt, “Outgrowth endothelial cells: characterization
and their potential for reversing ischemic retinopathy,” Inves-
tigative Ophthalmology and Visual Science, vol. 51, no. 11, pp.
5906–5913, 2010.
[6] C. Kalka, H. Masuda, T. Takahashi et al., “Transplantation of
ex vivo expanded endothelial progenitor cells for therapeutic
neovascularization,” Proceedings of the National Academy of
SciencesoftheUnitedStatesofAmerica,vol.97,no.7,pp.3422–
3427, 2000.
[7] J. Tongers, D. W. Losordo, and U. Landmesser, “Stem and pro-
genitor cell-based therapy in ischaemic heart disease: promise,
uncertainties,andchallenges,”EuropeanHeartJournal,vol.32,
no. 10, pp. 1197–1206, 2011.
[8] G. P. Fadini, C. Agostini, and A. Avogaro, “Autologous stem
cell therapy for peripheral arterial disease meta-analysis and
systematic review of the literature,” Atherosclerosis, vol. 209,
no. 1, pp. 10–17, 2010.
[9] A.ColmanandO.Dreesen,“Pluripotentstemcellsanddisease
modeling,” Cell Stem Cell, vol. 5, no. 3, pp. 244–247, 2009.
[10] K. Saha and R. Jaenisch, “Technical challenges in using human
induced pluripotent stem cells to model disease,” Cell Stem
Cell, vol. 5, no. 6, pp. 584–595, 2009.
[11] A. W. Stitt, C. L. O’Neill, M. T. O’Doherty, D. B. Archer, T. A.
Gardiner, and R. J. Medina, “Vascular stem cells and ischaemic
retinopathies,”ProgressinRetinalandEyeResearch,vol.30,no.
3, pp. 149–166, 2011.
[12] E. M. Van Craenenbroeck, V. M. Conraads, D. R. Van Bock-
staele et al., “Quantiﬁcation of circulating endothelial progen-
itor cells: a methodological comparison of six ﬂow cytometric
approaches,” Journal of Immunological Methods, vol. 332, no.
1-2, pp. 31–40, 2008.
[13] J. Hur, C. H. Yoon, H. S. Kim et al., “Characterization of two
types of endothelial progenitor cells and their diﬀerent con-
tributions to neovasculogenesis,” Arteriosclerosis, Thrombosis,
and Vascular Biology, vol. 24, no. 2, pp. 288–293, 2004.
[14] R. J. Medina, C. L. O’Neill, M. Sweeney et al., “Molecular
analysis of endothelial progenitor cell (EPC) subtypes reveals
two distinct cell populations with diﬀerent identities,” BMC
Medical Genomics, vol. 3, article no. 18, 2010.
[15] R. J. Medina, C. L. O’Neill, T. M. O’Doherty et al., “Myeloid
angiogenic cells act as alternative M2 macrophages and mod-
ulateangiogenesisthroughinterleukin-8,”MolecularMedicine,
vol. 17, no. 9-10, pp. 1045–1055, 2011.
[16] T. Asahara, A. Kawamoto, and H. Masuda, “Concise review:
circulating endothelial progenitor cells for vascular medicine,”
Stem Cells, vol. 29, no. 11, pp. 1650–1655, 2011.
[17] Y. Lin, D. J. Weisdorf, A. Solovey, and R. P. Hebbel, “Origins of
circulating endothelial cells and endothelial outgrowth from
blood,” The Journal of Clinical Investigation, vol. 105, no. 1, pp.
71–77, 2000.
[18] M. C. Yoder, L. E. Mead, D. Prater et al., “Redeﬁning endothe-
lial progenitor cells via clonal analysis and hematopoietic
stem/progenitor cell principals,” Blood, vol. 109, no. 5, pp.
1801–1809, 2007.
[19] A.Reinisch,N.A.Hofmann,A.C.Obenaufetal.,“Humanized
large-scale expanded endothelial colony-forming cells func-
tion in vitro and in vivo,” Blood, vol. 113, no. 26, pp. 6716–
6725, 2009.
[20] D. A. Ingram, L. E. Mead, H. Tanaka et al., “Identiﬁcation of
a novel hierarchy of endothelial progenitor cells using human
peripheral and umbilical cord blood,” Blood, vol. 104, no. 9,
pp. 2752–2760, 2004.
[21] H. Bompais, J. Chagraoui, X. Canron et al., “Human endothe-
lial cells derived from circulating progenitors display speciﬁc
functional properties compared with mature vessel wall
endothelial cells,” Blood, vol. 103, no. 7, pp. 2577–2584, 2004.
[22] N. Mukai, T. Akahori, M. Komaki et al., “A comparison
of the tube forming potentials of early and late endothelial
progenitor cells,” Experimental Cell Research, vol. 314, no. 3,
pp. 430–440, 2008.
[ 2 3 ]P .A u ,L .M .D a h e r o n ,D .G .D u d ae ta l . ,“ D i ﬀerential in vivo
potential of endothelial progenitor cells from human umbili-
cal cord blood and adult peripheral blood to form functional
long-lasting vessels,” Blood, vol. 111, no. 3, pp. 1302–1305,
2008.
[24] J. M. Melero-Martin, M. E. De Obaldia, S. Y. Kang et al.,
“Engineering robust and functional vascular networks in vivo
w i t hh u m a na d u l ta n dc o r db l o o d - d e r i v e dp r o g e n i t o rc e l l s , ”
Circulation Research, vol. 103, no. 2, pp. 194–202, 2008.
[25] W. Chris Shelley, A. C. Leapley, P. J. Critser et al., “Changes
in the frequency and in vivo vessel-forming ability of rhesus
monkey circulating endothelial colony—forming cells across
the lifespan (birth to aged),” Pediatric Research Advanced
Online Publication, vol. 71, no. 2, pp. 156–161, 2012.
[ 2 6 ]T .H e ,L .A .S m i t h ,S .H a r r i n g t o n ,K .A .N a t h ,N .M .C a p l i c e ,
and Z. S. Katusic, “Transplantation of circulating endothelialStem Cells International 5
progenitor cells restores endothelial function of denuded
rabbit carotid arteries,” Stroke, vol. 35, no. 10, pp. 2378–2384,
2004.
[ 2 7 ]C .D u b o i s ,X .L i u ,P .C l a u se ta l . ,“ D i ﬀerential eﬀects of
progenitor cell populations on left ventricular remodeling and
myocardial neovascularization after myocardial infarction,”
Journal of the American College of Cardiology, vol. 55, no. 20,
pp. 2232–2243, 2010.
[28] G. P. Fadini, S. Sartore, M. Albiero et al., “Number and func-
tion of endothelial progenitor cells as a marker of severity for
diabeticvasculopathy,”Arteriosclerosis,Thrombosis,andVascu-
lar Biology, vol. 26, no. 9, pp. 2140–2146, 2006.
[29] C. J. Loomans, E. J. de Koning, F. J. Staal et al., “Endothelial
progenitor cell dysfunction: a novel concept in the patho-
genesis of vascular complications of type 1 diabetesiﬀerential
eﬀects of progenitor cell populations on left ventricular
remodeling and myocardial neovascularization after myocar-
dial infarction,” Diabetes, vol. 53, no. 1, pp. 195–199, 2004.
[30] K. Takahashi, K. Tanabe, M. Ohnuki et al., “Induction of
pluripotentstemcellsfromadulthumanﬁbroblastsbydeﬁned
factors,” Cell, vol. 131, no. 5, pp. 861–872, 2007.
[31] P. Au, J. Tam, D. Fukumura, and R. K. Jain, “Bone marrow
derived mesenchymal stem cells facilitate engineering of long-
lasting functional vasculature,” Blood, vol. 111, no. 9, pp.
4551–4558, 2008.
[32] D. O. Traktuev, D. N. Prater, S. Merfeld-Clauss et al., “Robust
functional vascular network formation in vivo by cooperation
of adipose progenitor and endothelial cells,” Circulation
Research, vol. 104, no. 12, pp. 1410–1420, 2009.
[33] P.Campagnolo, D.Cesselli,A.AlHaj Zen etal., “Human adult
vena saphena contains perivascular progenitor cells endowed
with clonogenic and proangiogenic potential,” Circulation,
vol. 121, no. 15, pp. 1735–1745, 2010.
[34] C. H. Yoon, J. Hur, K. W. Park et al., “Synergistic neovascu-
larization by mixed transplantation of early endothelial pro-
genitor cells and late outgrowth endothelial cells: The role of
angiogenic cytokines and matrix metalloproteinases,” Circula-
tion, vol. 112, no. 11, pp. 1618–1627, 2005.
[ 3 5 ]A .R u s t o m ,R .S a ﬀrich, I. Markovic, P. Walther, and H. H.
Gerdes, “Nanotubular highways for intercellular organelle
transport,” Science, vol. 303, no. 5660, pp. 1007–1010, 2004.
[36] J. L. Spees, S. D. Olson, M. J. Whitney, and D. J. Prockop,
“Mitochondrial transfer between cells can rescue aerobic res-
piration,”ProceedingsoftheNationalAcademyofSciencesofthe
United States of America, vol. 103, no. 5, pp. 1283–1288, 2006.
[37] K.Yasuda,A.Khandare,L.Burianovskyyetal.,“Tunnelingna-
notubes mediate rescue of prematurely senescent endothelial
cells by endothelial progenitors: exchange of lysosomal pool,”
Aging, vol. 3, no. 6, pp. 597–608, 2011.
[38] M. C. Deregibus, V. Cantaluppi, R. Calogero et al., “Endothe-
lialprogenitorcellderivedmicrovesiclesactivateanangiogenic
program in endothelial cells by a horizontal transfer of
mRNA,” Blood, vol. 110, no. 7, pp. 2440–2448, 2007.
[39] J. Skog, T. Wurdinger, S. van Rijn et al., “Glioblastoma mi-
crovesicles transport RNA and proteins that promote tumour
growth and provide diagnostic biomarkers,” Nature Cell Biol-
ogy, vol. 10, no. 12, pp. 1470–1476, 2008.
[40] G. Piaggio, V. Rosti, M. Corselli et al., “Endothelial colony-
forming cells from patients with chronic myeloproliferative
disorderslackthedisease-speciﬁcmolecularclonalitymarker,”
Blood, vol. 114, no. 14, pp. 3127–3130, 2009.
[41] A. L. Fernandez, F. Sanz-Rodriguez, R. Zarrabeitia et al.,
“Blood outgrowth endothelial cells from hereditary haemor-
rhagic telangiectasia patients reveal abnormalities compatible
with vascular lesions,” Cardiovascular Research, vol. 68, no. 2,
pp. 235–248, 2005.
[42] M. Toshner, R. Voswinckel, M. Southwood et al., “Evidence of
dysfunction of endothelial progenitors in pulmonary arterial
hypertension,” American Journal of Respiratory and Critical
Care Medicine, vol. 180, no. 8, pp. 780–787, 2009.
[43] R.D.Starke,F.Ferraro,K.E.Paschalakietal.,“Endothelialvon
Willebrand factor regulates angiogenesis,” Blood, vol. 117, no.
3, pp. 1071–1080, 2011.
[44] D. A. Ingram, I. Z. Lien, L. E. Mead et al., “In vitro hyper-
glycemia or a diabetic intrauterine environment reduces neo-
natal endothelial colony-forming cell numbers and function,”
Diabetes, vol. 57, no. 3, pp. 724–731, 2008.